Status and phase
Conditions
Treatments
About
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients are included in the study if all of the following criteria are met:
Exclusion criteria
Patients are excluded from participating in this study if 1 or more of the following criteria are met:
Primary purpose
Allocation
Interventional model
Masking
511 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal